DURHAM — Duke University researchers have received $1.3 million from Charles and Daneen Stiefel of Raleigh to study immune disorders that lead to cancer.
The gift will go to research into the genetic mechanisms that cause Common Variable Immune Deficiency, a condition in which patients have low antibodies that leave them vulnerable to infections and lymphoma, a type of blood cancer.
Researchers at Duke have already defined the genetic makeup of CVID. Duke officials say the gift from the Stiefels will allow scientists to look further at the mutations in order to better diagnose the disease.
Charles Stiefel, a member of the Duke Medicine Board of Visitors, is a former chairman and CEO of Stiefel Laboratories Inc., a company specializing in dermatological products. Daneen Stiefel is a former vice president at the company, which was sold to GlaxoSmithKline in 2009 for $3.6 billion.
One of the couples two children is a Duke alumnus.